DGAP-News

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA(R)) for Pancreatic Cancer

DGAP-News: ERYTECH PHARMA SA / Key word(s): Study
ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase
(GRASPA(R)) for Pancreatic Cancer

26.09.2016 / 10:38
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase
(GRASPA(R)) for Pancreatic Cancer

Primary data read-out from the trial expected by early 2017

Lyon (France), September 26, 2016 - ERYTECH Pharma (Euronext Paris: ERYP),
a French biopharmaceutical company developing 'tumor starvation' treatments
for acute leukemia and other oncology indications with unmet medical needs,
today announced the final patient has been enrolled in its Phase 2 trial of
eryaspase, also known as ERY-ASP or GRASPA(R), for the treatment of
pancreatic cancer.

The multicenter, randomized Phase 2 trial is evaluating eryaspase as a
second-line treatment of patients with metastatic pancreatic cancer. In the
study conducted in France, eryaspase was added to the standard of care
(currently Gemcitabine or FOLFOX regimen) and then compared to the standard
of care alone in a 2-to-1 randomization. The primary endpoint of the trial
is progression-free survival (PFS) at four months.

The trial has completed enrollment of 139 patients and we expect to report
primary results from this trial by early 2017.

"The Phase 2 trial of eryaspase for pancreatic cancer is, to our knowledge,
the largest cohort of solid tumor patients treated with an asparaginase-
based product to date," said Gil Beyen, Chairman and CEO of ERYTECH.
"Previously, deprivation of asparagine has shown to limit growth of
pancreatic and other solid tumors in preclinical models, but clinical proof
of concept has not yet been established. We believe a positive efficacy
signal in this trial could open a potentially large application area for
asparagine depletion in certain solid tumors."

About pancreatic cancer:

Pancreatic cancer is a disease in which malignant (cancer) cells are found
in the tissues of the pancreas. Every year there are about 150,000 new
cases of pancreatic cancer diagnosed in Europe and the United States.
Pancreatic cancer is a particularly aggressive cancer, with a five-year
survival rate of less than 10% and is currently the fourth most common
cause of cancer death in the EU for men and women. Pancreatic cancer could
be a suitable indication for eryaspase because it involves a large
proportion of tumors that are believed to be sensitive to asparagine